HistoSonics Targets Interventional Oncologists With Histotripsy Clinical Forum at SIO Conference

A LinkedIn post from HistoSonics describes the company’s planned presence at the Society of Interventional Oncology (SIO) conference in Savannah, Georgia, from February 4–8. The post highlights an invitation-only, peer-driven dinner forum titled “Histotripsy in Practice: A Clinical Forum,” scheduled for Friday, February 6 from 7:30–9:30 p.m. at the Chart House Savannah, moderated by interventional radiologist Dr. Paul Laeseke of the University of Wisconsin and HistoSonics’ VP of Clinical Affairs, Amanda Cafaro. Interested attendees are encouraged to RSVP via an online form due to limited space. The post also notes that the HistoSonics team will be available at booth #500 on the exhibition floor to discuss the Edison Histotripsy System, with a disclaimer that use of the Edison System outside liver applications is currently limited to clinical investigations.

From an investor perspective, the post suggests that HistoSonics is actively engaging with interventional oncology specialists and current or prospective users of its histotripsy technology in a focused, educational setting. This type of peer-driven clinical forum may support physician adoption, real-world feedback, and clinical positioning of the Edison System, particularly within liver applications where commercial use appears most advanced. The company’s visibility at a specialized conference and emphasis on clinical practice discussion could help strengthen its network of key opinion leaders and potentially accelerate utilization as regulatory and reimbursement pathways evolve. However, the explicit limitation of the Edison System to clinical investigations outside liver applications underscores that broader indications remain in development and may still be subject to regulatory and clinical trial outcomes, which could affect the pace and scale of future revenue growth.